drugset
drugset / Trial / NCT04207840

Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals

NCT04207840 ↗

Phase 4 Completed 28 enrolled Amphastar Pharmaceuticals, Inc.
RandomizedCrossoverSingle-blindTreatment

Summary

To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.

Timeline

Start
2019-12-09
Primary completion
2019-12-20
Completion
2019-12-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinephrine Other / unclassified 0.25 mg Inhaled
Subject Epinephrine Other / unclassified 0.3 mg Inhaled
Subject Salbutamol Unknown 0.18 mg Inhaled

Indications

anaphylaxis asthma